Bruker Corp (FRA:BKD)
€ 59.28 1.32 (2.28%) Market Cap: 8.99 Bil Enterprise Value: 10.02 Bil PE Ratio: 23.53 PB Ratio: 6.64 GF Score: 95/100

Bruker Corp at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 08:40PM GMT
Release Date Price: €48.4 (+1.26%)
Casey Rene Woodring
JPMorgan Chase & Co, Research Division - Research Analyst

Hi, everyone. Welcome to the 2021 JPMorgan Healthcare Conference. My name is Casey Woodring. I'm a member of the life science tools and diagnostics equity research team here at JPMorgan. Today, it's my pleasure to introduce the management team from Bruker. (Operator Instructions)

And with that, let me turn it over to Frank.

Frank H. Laukien
Bruker Corporation - Chairman, CEO & President

Thank you, Casey. Pleasure to be here. Hello, everyone. Given the shortened format of the presentation this year, I do not intend to give you a complete overview of Bruker, but instead give you an update on how our strategy is evolving in 2021 and beyond. I will briefly touch on our Q4 -- give you a Q4 update and briefly touch on some preliminary view -- not yet guidance, preliminary view of 2021. But mostly, I'd like to talk to you about Project Accelerate 2.0, as we call it. It is Project Accelerate, our fast -- our high-growth, high-margin initiatives, but several of them, in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot